Markel Group Inc. Purchases 1,000 Shares of Thermo Fisher Scientific Inc. $TMO

Markel Group Inc. increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.4% during the third quarter, Holdings Channel reports. The fund owned 74,100 shares of the medical research company’s stock after purchasing an additional 1,000 shares during the quarter. Markel Group Inc.’s holdings in Thermo Fisher Scientific were worth $50,021,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently bought and sold shares of TMO. Legacy Wealth Managment LLC ID increased its stake in shares of Thermo Fisher Scientific by 78.6% in the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 22 shares during the period. Kilter Group LLC bought a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $25,000. Allied Private Wealth LLC acquired a new position in Thermo Fisher Scientific during the 2nd quarter worth $26,000. Pingora Partners LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter worth $30,000. Finally, Navigoe LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter worth $31,000. 89.23% of the stock is currently owned by institutional investors.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Michael D. Shafer sold 25,500 shares of the stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total value of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at $77,982,284.75. The trade was a 7.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 76,199 shares of company stock worth $45,896,780. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of NYSE TMO opened at $698.24 on Wednesday. The stock has a fifty day moving average price of $657.33 and a two-hundred day moving average price of $553.71. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.41 and a current ratio of 1.81. The firm has a market cap of $258.71 billion, a P/E ratio of 36.83, a PEG ratio of 2.78 and a beta of 0.84. Thermo Fisher Scientific Inc. has a 1 year low of $435.27 and a 1 year high of $711.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $0.28. Thermo Fisher Scientific had a return on equity of 17.33% and a net margin of 14.94%. The company had revenue of $12.14 billion for the quarter, compared to analysts’ expectations of $11.95 billion. During the same period last year, the firm earned $5.79 EPS. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. Research analysts forecast that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on TMO shares. BMO Capital Markets cut shares of Thermo Fisher Scientific to a “market perform” rating in a research note on Wednesday, September 9th. HSBC upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 1st. Piper Sandler assumed coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, September 9th. They set an “overweight” rating on the stock. Stifel Nicolaus boosted their price target on shares of Thermo Fisher Scientific from $650.00 to $775.00 and gave the stock a “buy” rating in a research report on Thursday, October 22nd. Finally, Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 3rd. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $689.10.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.